Introduction
logical fluid or the intracellular environment. Thus, safety Overexpression of the HER-2/neu (also called c-erbB -2) concerns related to the vector are minimized. In fact, proto-oncogene occurs in many human cancer cells, studies from other groups have shown the low toxicity including approximately 30% of breast cancer and of DNA-liposome complex administration in mice, [15] [16] [17] ovarian cancer; and it is correlated with poor patient nonhuman primates 15, 17 and humans. [18] [19] [20] Repeated prognosis and shorter survival. [1] [2] [3] [4] Because down-reguadministration of DNA-liposome complex can be practilation of HER-2/neu is able to reverse the transformation cally performed to reach higher gene transfer efficiency. of cancer cells, 5-7 HER-2/neu is considered an ideal target Cationic liposomes are widely used in preclinical studies for cancer therapy. [7] [8] [9] [10] This concept is evidenced by our to deliver the genes of interest.
9,10, [21] [22] [23] previous finding that adenovirus 5 E1A, a well-known In our previous studies, we used the DOPE/DCtranscription factor 11 and the early gene that is expressed chol(dioleoyl-phosphatidylethanolamine/3b [N-(N′,N′-after virus infection, inhibits HER-2/neu transcription dimethylaminoethane) carbamoyl] cholesterol) cationic as well as suppresses transformation and tumoriliposome 24 to deliver the adenovirus E1A gene to mice genicity induced by HER-2/neu-overexpression in cancer bearing HER-2/neu-overexpressing human ovarian cells.
5,12-14 Thus, E1A has great potential for use in gene tumors. 10 Expression of E1A and down-regulation of therapy aiming at the HER-2/neu-overexpressing HER-2/neu-encoded p185 protein were detected in the human cancers.
tumor tissues, and approximately 70% of the treated aniCationic liposomes are the key to gene therapy studies mals survived for more than 1 year. These results suggest as a nonviral vector. DNA-cationic liposome complex has that cationic liposome-mediated E1A gene transfer may been shown to efficiently transfect genes into a variety of be a promising therapeutic strategy for HER-2/neu-overtissues. It has advantages in several aspects compared expressing cancers. with adenoviral and retroviral vectors: genes transduced Based on these preclinical studies, we planned to start by cationic liposomes are transiently expressed, less a phase I clinical trial in patients with HER-2/neu-overexlikely to be integrated into chromosomes, and are less pressing breast and ovarian cancers using E1A-liposome likely to be able to allow propagation in cells. Lipids are complex. We conducted a series of studies to evaluate the safety of the intraperitoneal administration of E1A, using cumulative DNA and lipid doses equivalent to five to 40 series of intraperitoneal injections of E1A-liposome com-
Results and discussion
plex had neither lethal effects nor any signs of acute or residual toxic effects in mice over a 14-day observation Acute toxicity study period, even in the dosage as high as 10 times the proTo test the safety profile of the intraperitoneal injection posed human dose. On the basis of these results, E1A of the E1A-liposome complex and to select the highest dosages of 15, 30, 60 and 120 g were chosen for the dosage for a later repeated-dose study, 25 six groups of further repeat-dose study, ie after five consecutive daily mice were given single intraperitoneal injections of a injections, the cumulative doses are 5 to 40 times the prowide range of E1A doses. The effective dose used in our posed human dose for future phase I clinical trial. previous preclinical gene therapy animal protocol was 15 g, 8,10 which would be equivalent to the starting dose in our future phase I trial. In this experiment, each mouse
Repeat-dose safety study received either 7.5 g, 15 g, 30 g, 60 g, 120 g or 150
To assess further the safety of repeated doses of the E1A-g of E1A DNA. These doses were 0.5-10 times the startliposome complex, five groups of five ICR mice each ing dose proposed for our future phase I trial. 26 Control were treated intraperitoneally on a daily basis for 5 conmice were injected with medium only. Mice were secutive days, at an E1A dosage of 15, 30, 60 or 120 g observed for clinical signs of toxicity daily, killed after 14 for each injection respectively, one group of mice were days, and analyzed for hepatic and renal function and injected with medium as a negative control. No signs of gross pathology.
clinical toxicity were observed at any of these dose levels Major organ functions such as hepatic and renal funcduring the 6-week observation period, and no E1A-tions were found to be normal in all appropriate groups related adverse effects were observed on the group body by proper biochemical assays (Table 1 ). All organs had normal gross pathology (data not shown). Thus, this weight or group daily food consumption. Mice were killed and necropsied for further analysis 6 weeks after alterations in the spleen did occur with greater frequency in treated animals; however, this is usually thought to be the final injection.
Clinical chemistry and hematological analyses were an incidental and nonspecific finding in this strain of mice. Thus, these changes were not deemed significant.
27
performed on blood samples. The biochemical measurements of serum glutamic-oxaloacetic transaminase These data suggest that repeated-dose treatments with E1A-liposome did not result in significant lesions in the (SGOT) and blood creatinine are shown in Table 2 . The SGOTs lay within the normal value range, suggesting major organs tested; since cationic liposome induces transgene expression in cells transiently, observation of that all these groups of mice had normal hepatic function. The creatinine assays gave biochemical values that reflect up to 6 weeks after injection is long enough to detect the adverse effects if there are any. Therefore, the proposed normal kidney functions. Blood counts are shown in Table 3 for the mice treated with the proposed dose of dosage administration of E1A-liposome complex in humans would not be expected to cause any organ path-E1A-liposome complex for the proposed clinical study or the control reagent. The parameters indicate normal ology for patients. Pathologic studies were also performed on mice at difhematological values for these treated animals.
The safety profile of E1A-liposome was also assessed ferent time-points after a single injection at 10 times the proposed dose. The tissues were collected at selected histopathologically. Brain, heart, liver, kidney, lung and spleen were examined. There were no significant microtime-points from several hours up to 14 days after injection. No biologically significant alterations in the tissues scopic lesions observed that correlated with E1A-liposome administration (Table 4) . Focal invasion of lymphofrom three groups of mice were observed. In the remaining mice, alterations potentially attributable to E1A-lipocytes, hemorrhage, and congestion found in the lungs were observed in some mice, however, these are most some complex administration were generally minimal and highly localized (Table 5) . Thus, our conclusion from likely related to carbon dioxide poisoning which is used when killing the mice. Slight focal invasion of lymphothese experiments is that the proposed human dose is a safe starting dose of E1A-liposome complex for the phase cytes occurred in the kidney and liver, which is also a normal occurrence for this strain of mice. 27 In the spleens, I clinical trial. Similarly, other groups reported the lack of toxicity three kinds of lymphoid hyperplasia and the formation of follicles with germinal centers in the marginal zones using the cationic liposome as a gene delivery system. The safety profile of plasmid DNA and DMRIE/DOPE of the white pulp were observed. Most of these In light of the toxicity data reported here, the E1A- Committee of the National Institutes of Health and the National Food and Drug Administration. Liposome-E1A complex E1A DNA was prepared by bacterial fermentation and extracted using a Wizard DNA Maxi-preparation kit (Promega, Madison, WI, USA). DNA was precipitated with ethanol and resuspended in sterilized TE buffer. The liposome complex administration was evaluated in rodcationic liposome was made in Dr Leaf Huang's laboraents and nonhuman primates by Parker et al. 17 Compared tory in the University of Pittsburgh, by mixing DC-chol:-with our studies, the liposome formulation is different, DOPE in a molar ratio of 6:4. 24 The E1A-liposome comlower dosage lipid was tested, and intravenous and plex was prepared under aseptic conditions on each day intrahepatic injection were performed. However, no sigof dosing by diluting the proper amount of E1A-expressnificant adverse effects, no autoimmunity and organ toxing vector in DMEM/F-12 serum-free medium and then icity were found to be associated with the DNA-liposome mixing with the cationic liposome DC-chol:DOPE at a complex administration. In another study, patients with ratio of 15 g DNA:200 nmol liposome to reach 200 l. late stage melanoma were treated by intratumor injection This mixture was then incubated at 37°C for 10 min with plasmid DNA encoding major histocompatibility before injection. DMEM/F-12 serum-free medium was complex HLA-B7 protein complexing with the used as a control. DOPE/DC-chol liposome. 18 The protein expression in tumor nodules was detected, and tumors were found regressive in some cases, but no toxicity and anti-DNA Acute toxicity study Thirty mice were separated into six groups of five mice antibody was detected in any patients. Together with our safety studies reported here, these findings suggest that each. Each group of mice received a different E1A-liposome dose: 7.5, 15, 30, 60, 120 or 150 g in a single intracationic liposome by several routes of administration is a gene delivery system with efficient gene transfer and peritoneal injection. These doses were 0.5-10 times the proposed E1A-liposome complex starting dose for the minimum adverse effects.
